Categories
Change Password!
Reset Password!
Previous investigation has proceeded into composing medicines that can be applied to relieve endometriosis-associated symptoms.
Various
medication and treatment methods are established for endometriosis and it has
been a matter of great interest for research. In this study, it is established
that the new GnRH antagonist called Elagolix has been efficacious to treat
endometriosis.
Previous investigation has proceeded into composing
medicines that can be applied to relieve endometriosis-associated symptoms.
Along with already verified medicines, a new GnRH antagonist, Elagolix, is in
progress. The authenticity of this drug compared to other GnRH antagonists is
the nonpeptide structure that enables it to be delivered orally.
Analysis of various Phase I, II and III clinical trials
that have estimated the efficacy and safety of Elagolix were done. As many
medicines on the market have acclaimed for the treatment of
endometriosis-related indications, the proof of superiority or equality of
effect, patient compliance as well as tolerability should be evaluated while
proposing a new drug.
Elagolix may have a benefit over previous GnRH agonists,
in that it is not involved with 'flare-up' effect, it too, takes a toll on bone
mineral density.
Nonetheless, investigations have shown that the Elagolix
is well tolerated, and with mild or moderate side effects. But, investigations
are still required to evaluate whether Elagolix can compete with or establish
gold-standard medical therapies in this field, more investigations that directly
compare Elagolix to said treatments, might be required.
Expert Opin Pharmacother. 2017 Jul 24
Efficacy of Elagolix in the treatment of endometriosis.
Perricos A et al.
Comments (0)